What's Happening?
Kayla Barnes-Lentz, a 35-year-old host of the 'Longevity Optimization Podcast,' is actively pursuing experimental treatments to delay menopause until she is 60. Her approach focuses on addressing three key aspects of ovarian aging: the loss of eggs, mitochondrial
dysfunction, and the thickening of ovarian tissue. Barnes-Lentz is utilizing rapamycin, a drug under study for its potential to reduce egg loss, and engaging in high-intensity interval training and red light therapy to support mitochondrial health. Additionally, she undergoes hyperbaric oxygen therapy to improve blood flow and potentially slow ovarian tissue thickening. Barnes-Lentz also emphasizes environmental factors, having moved from Los Angeles to Texas to avoid air toxins, and is considering future stem cell treatments.
Why It's Important?
The pursuit of delaying menopause has significant implications for women's health and longevity. By potentially extending the fertile years, women like Barnes-Lentz aim to balance career and family planning more effectively. This approach could also contribute to broader longevity goals by maintaining ovarian health, which is crucial for overall well-being. The experimental nature of these treatments highlights the need for more research and data, especially concerning women's health and aging. If successful, these interventions could pave the way for new medical protocols and enhance the quality of life for women approaching menopause.
What's Next?
Barnes-Lentz plans to continue her health optimization protocol and explore additional interventions, such as stem cell treatments, to further delay menopause. She intends to test a mitochondrial cocktail of supplements and is keen on contributing to research that could provide answers about hormonal health and aging. As she aims to get pregnant later this year, her ongoing efforts may offer valuable insights into the effects of these treatments on fertility and post-partum health.
